Developing consistent, predictive human iPSC-derived hepatocytes to improve translational research and toxicity testing

Early‑stage drug discovery increasingly relies on liver models for physiologically relevant insight, yet many of these systems still lack the reliable and reproducible data needed for confident predictive toxicology. Primary human hepatocytes (PHHs) are the commonly used model for predictive screening of drug‑induced liver injury (DILI); however, their poor longevity in culture, batch variability, and limited availability make it challenging to identify liabilities early. The need for more scalable, consistent and high‑fidelity liver models has never been more critical.

To address these challenges, join Principal Scientist Dr Gianmarco Mastrogiovanni in this SelectScience® webinar as he demonstrates how scalable, consistent ioHepatocytes can be applied for DILI prediction. Using opti‑ox™ deterministic cell programming, these iPSC‑derived hepatocytes achieve the reproducibility, scale and functional maturity needed to overcome PHH limitations, and Dr Mastrogiovanni will show how their performance supports more reliable early ADME‑toxicology and safety assessment.